Unità Terapia Intensiva Ematologica e terapia cellulari - casa della sofferenza
Welcome,         Profile    Billing    Logout  
 3 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Carella, Angelo Michele
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25
GITMO-PHYLOS, NCT03270748: Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

Completed
2
78
Europe
GvHD prophylaxis
Gruppo Italiano Trapianto di Midollo Osseo
Myeloid Malignancies
11/22
11/22
DEC GITMO, NCT04476199 / 2020-002297-26: Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT

Active, not recruiting
2
100
Europe
Venetoclax and Decitabine
Gruppo Italiano Trapianto di Midollo Osseo, Abbvie, Janssen
Acute Myeloid Leukemia
02/23
06/25
NCT06682637: Melflufen for Elderly Patients With Relapsed Myeloma

Not yet recruiting
2
30
Europe
Melflufen, Dexamethasone
Fondazione EMN Italy Onlus
Relapse Multiple Myeloma
02/27
08/27
CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting
N/A
954
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi
Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19
09/24
09/24
GIMEMA, NCT06657846: HRQoL and Financial Toxicity in Patients with VEXAS Syndrome

Not yet recruiting
N/A
100
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
VEXAS
02/25
06/25

Download Options